Latest news with #TaraBancroft
Business Insider
14-05-2025
- Business
- Business Insider
TD Cowen Remains a Hold on Fate Therapeutics (FATE)
TD Cowen analyst Tara Bancroft maintained a Hold rating on Fate Therapeutics (FATE – Research Report) yesterday. The company's shares closed yesterday at $1.00. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Bancroft is an analyst with an average return of -15.7% and a 20.31% success rate. Bancroft covers the Healthcare sector, focusing on stocks such as Geron, Merus, and Vaxcyte. Fate Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.17. FATE market cap is currently $122.6M and has a P/E ratio of -0.65.
Business Insider
14-05-2025
- Business
- Business Insider
TD Cowen Sticks to Its Hold Rating for MacroGenics (MGNX)
TD Cowen analyst Tara Bancroft maintained a Hold rating on MacroGenics (MGNX – Research Report) today. The company's shares closed today at $1.54. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Bancroft covers the Healthcare sector, focusing on stocks such as Geron, Merus, and Vaxcyte. According to TipRanks, Bancroft has an average return of -15.7% and a 20.31% success rate on recommended stocks. MacroGenics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00. The company has a one-year high of $5.77 and a one-year low of $0.99. Currently, MacroGenics has an average volume of 730.7K.
